Institut National de la Santé Et de la Recherche Médicale, France
Quick facts
Marketed products
- Anti-H1N1v Vaccine · Immunology / Infectious Disease
This vaccine stimulates the immune system to produce antibodies and cellular immunity against the H1N1 influenza virus. - curcuma longa
- Rapamycin · Oncology
Phase 3 pipeline
- Bilhvax vaccine (Sh28GST) · Infectious Disease / Parasitology
Bilhvax is a recombinant vaccine targeting schistosome antigens to induce immune responses against Schistosoma haematobium infection.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Institut National de la Santé Et de la Recherche Médicale, France portfolio CI brief
- Institut National de la Santé Et de la Recherche Médicale, France pipeline updates RSS
Frequently asked questions about Institut National de la Santé Et de la Recherche Médicale, France
What are Institut National de la Santé Et de la Recherche Médicale, France's marketed drugs?
Top marketed products include Anti-H1N1v Vaccine, curcuma longa, Rapamycin.
What is Institut National de la Santé Et de la Recherche Médicale, France's pipeline?
Institut National de la Santé Et de la Recherche Médicale, France has 1 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include Bilhvax vaccine (Sh28GST).
Related
- Anti-H1N1v Vaccine · Immunology / Infectious Disease
- curcuma longa
- Rapamycin · Oncology
- Sector hub: All tracked pharma companies